Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report
Zhe Yu,1,* Wei Wei,1,* Hongruo Liu,1 Evenki Pan,2 Peng Yang,2 Kui Jiang1 1Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Nanjing Genesseq Technology Inc., Nanjing, Jiangsu, People’s Republic of China*These a...
Main Authors: | , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/5d35a63a08f5485ab628ffdc6709b4e2 |
id |
ftdoajarticles:oai:doaj.org/article:5d35a63a08f5485ab628ffdc6709b4e2 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:5d35a63a08f5485ab628ffdc6709b4e2 2023-05-15T16:09:10+02:00 Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report Yu Z Wei W Liu H Pan E Yang P Jiang K 2021-12-01T00:00:00Z https://doaj.org/article/5d35a63a08f5485ab628ffdc6709b4e2 EN eng Dove Medical Press https://www.dovepress.com/efficient-everolimus-treatment-for-metastatic-castration-resistant-pro-peer-reviewed-fulltext-article-OTT https://doaj.org/toc/1178-6930 1178-6930 https://doaj.org/article/5d35a63a08f5485ab628ffdc6709b4e2 OncoTargets and Therapy, Vol Volume 14, Pp 5423-5428 (2021) castration resistant prostate cancer androgen receptor everolimus next-generation sequencing Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 article 2021 ftdoajarticles 2022-12-31T09:29:52Z Zhe Yu,1,* Wei Wei,1,* Hongruo Liu,1 Evenki Pan,2 Peng Yang,2 Kui Jiang1 1Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Nanjing Genesseq Technology Inc., Nanjing, Jiangsu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kui JiangDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaEmail jk0411@163.comAbstract: Metastatic castration resistant prostate cancer (mCRPC), the advanced stage of prostate cancer (PCa), develops resistance to first line androgen deprivation therapy (ADT). Aberrant androgen receptor (AR) and PI3K-Akt-mTOR signaling pathway are responsible for the development and progression of mCRPC. We herein describe a case of a 64-year-old male mCRPC patient with somatic AKT1 and AR mutations. The patient, who had been heavily pretreated by ADT and AR inhibitors, showed stable disease progression when he received everolimus, an mTOR inhibitor. The PSA level dropped drastically from 1493.0 ng/mL to 237.6 ng/mL, after 3 months of treatment. The overall survival (OS) was 43 months, of which the progression-free survival (PFS) with everolimus treatment was 7 months. The administration of mTOR inhibitor, everolimus, could achieve good clinical responses along with prolonging PFS for mCRPC patients harboring AKT1 mutations. Technology in precision medicine, such as targeted next-generation sequencing (NGS) of cancer-relevant genes, has promising function in personalized therapy.Keywords: castration resistant prostate cancer, androgen receptor, everolimus, next-generation sequencing Article in Journal/Newspaper Evenki Directory of Open Access Journals: DOAJ Articles Evenki ENVELOPE(132.817,132.817,59.683,59.683) |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
castration resistant prostate cancer androgen receptor everolimus next-generation sequencing Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
castration resistant prostate cancer androgen receptor everolimus next-generation sequencing Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yu Z Wei W Liu H Pan E Yang P Jiang K Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
topic_facet |
castration resistant prostate cancer androgen receptor everolimus next-generation sequencing Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
description |
Zhe Yu,1,* Wei Wei,1,* Hongruo Liu,1 Evenki Pan,2 Peng Yang,2 Kui Jiang1 1Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Nanjing Genesseq Technology Inc., Nanjing, Jiangsu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Kui JiangDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaEmail jk0411@163.comAbstract: Metastatic castration resistant prostate cancer (mCRPC), the advanced stage of prostate cancer (PCa), develops resistance to first line androgen deprivation therapy (ADT). Aberrant androgen receptor (AR) and PI3K-Akt-mTOR signaling pathway are responsible for the development and progression of mCRPC. We herein describe a case of a 64-year-old male mCRPC patient with somatic AKT1 and AR mutations. The patient, who had been heavily pretreated by ADT and AR inhibitors, showed stable disease progression when he received everolimus, an mTOR inhibitor. The PSA level dropped drastically from 1493.0 ng/mL to 237.6 ng/mL, after 3 months of treatment. The overall survival (OS) was 43 months, of which the progression-free survival (PFS) with everolimus treatment was 7 months. The administration of mTOR inhibitor, everolimus, could achieve good clinical responses along with prolonging PFS for mCRPC patients harboring AKT1 mutations. Technology in precision medicine, such as targeted next-generation sequencing (NGS) of cancer-relevant genes, has promising function in personalized therapy.Keywords: castration resistant prostate cancer, androgen receptor, everolimus, next-generation sequencing |
format |
Article in Journal/Newspaper |
author |
Yu Z Wei W Liu H Pan E Yang P Jiang K |
author_facet |
Yu Z Wei W Liu H Pan E Yang P Jiang K |
author_sort |
Yu Z |
title |
Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
title_short |
Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
title_full |
Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
title_fullStr |
Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
title_full_unstemmed |
Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report |
title_sort |
efficient everolimus treatment for metastatic castration resistant prostate cancer with akt1 mutation: a case report |
publisher |
Dove Medical Press |
publishDate |
2021 |
url |
https://doaj.org/article/5d35a63a08f5485ab628ffdc6709b4e2 |
long_lat |
ENVELOPE(132.817,132.817,59.683,59.683) |
geographic |
Evenki |
geographic_facet |
Evenki |
genre |
Evenki |
genre_facet |
Evenki |
op_source |
OncoTargets and Therapy, Vol Volume 14, Pp 5423-5428 (2021) |
op_relation |
https://www.dovepress.com/efficient-everolimus-treatment-for-metastatic-castration-resistant-pro-peer-reviewed-fulltext-article-OTT https://doaj.org/toc/1178-6930 1178-6930 https://doaj.org/article/5d35a63a08f5485ab628ffdc6709b4e2 |
_version_ |
1766405107957628928 |